Fumed Silica 380 m²/g: Properties, Thickening Performance and Applications

Published: Source: Silica Raw Materials News Section: Silica Raw Materials

📌 Key Takeaways

  • Topic: Silica MSDS: How to Read It and What Safety Information to Check
  • Keywords: food grade silica
  • Published: 2026-11-20 09:06:56
  • Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
To combat degradation and recrystallization, strategies such as surface functionalization with hydrophobic silanes, pore filling with polymeric co-formers, and selection of solvent-free loading methods (e.g., co-milling or melting) have been demonstrated to counteract water adsorption, increase drug-matrix interactions, and avoid solvent-templated polymorph formation. Tuning of pore size, surface chemistry, and loading processes allows MSNs to enable better long-term amorphous API stability and regulated polymorphism, thereby facilitating enhanced performance of nanoparticulate drug delivery systems.

What Is Colloidal Silica? Properties, Types and Uses in Polishing, Coatings and Binders

Precipitated Silica Supplier: How to Compare Grades, Pricing and Reliability
Submicron Spherical Silica: Specifications and Uses in Underfill and Advanced Packaging
Silica Gel Manufacturer: Product Types, Quality Standards and Selection Guide
44. Trzeciak K., Chotera-Ouda A., Bak-Sypien I.I., Potrzebowski M.J. Mesoporous silica particles as drug delivery systems - The state of the art in loading techniques and the recent progress in analytical approaches for monitoring these processes. Pharmaceutics. 2021;13:950. doi: 10.3390/pharmaceutics13070950. [ DOI ] [ PMC free post ] [ PubMed ] [ Google Scholar ]
Cabot Cab-O-Sil: Product Range, Key Grades and Alternatives
Magnetic particles were synthesized with an iron-containing coating. The model drugs were safranin O and hydrocortisone. The particles were functionalized with a bulky azo derivative to act as a gatekeeper and stop early leakage of the drug. In vitro release models have demonstrated that most of the drug is released only in the colon, as desired. This is owing to the reductive environment in the colon (the presence of the azoreductase enzyme), where the enzymatic degradation of the azo bond resulted in controlled release. In addition, in vivo pharmacokinetic studies were conducted in a rat model of induced colitis to test the effect of the magnetic field during therapy. The findings boosted when the rats wore a magnetic belt, which extended the retention time of the particles in the desired areas [ 75 ]. Zhang et al. presented a study in which magnetic silica nanoparticles (filled with sulforaphane) were developed for the treatment of myocardial infarction [ 38 ]. In mouse models, effective accumulation was observed in the infarcted zone after the application of an external magnetic field [ 33, 75 ]. These results show the potential of using magnetic particles with magnetic field guidance [ 33 ]. Radhakrishnan et al. developed a drug delivery system (DDS) loaded with carboplatin for targeted lung cancer therapy [ 63 ]. The DDS was core-shell mesoporous silica functionalized with folic acid. Initially, the drug loading capability of the functionalized carrier was more than twice as high per surface unit compared to the non-functionalized carrier due to the anchored -NH 2 groups. The drug release was sustained but limited (up to 36%) in the case of the functionalized particle, similarly to previous cases. This is most likely owing to the stronger interactions between the amine groups and the carboplatin. The amino-functionalized particles were further functionalized with folic acid to increase cellular uptake of the particles, demonstrating the potential of folic acid-targeted therapy [ 63, 65, 76 ]. Cancer cells typically overexpress folate receptors, resulting in folate-mediated internalization that preferentially targets these cells [ 63, 76 ]. This was demonstrated in a drug-mediated cytotoxicity analysis where amino- and folate-functionalized particles were evaluated and compared. Much greater cytotoxicity was observed in cells overexpressing folate receptors [ 63 ]. Similar research was carried out by Shirani et al., where folic acid functionalized MSNs were loaded with gemcitabine as a model drug, to investigate its potential in cancer treatment, while actively targeting cancer cells [ 70 ]. Outcomes have shown that higher cellular uptake (HeLa and K562 cells) was observed in the case of the functionalized particles, compared with the non-functionalized carriers [ 70 ]. Jafarpour et al. demonstrated the importance of functionalizing the carriers to accomplish targeted therapy utilizing methotrexate as a model drug [ 76 ]. The particles were grafted with a copolymer to act as a pH-responsive gatekeeper and folic acid to actively target cancer cells [ 76 ]. Ortiz et al. similarly designed a pH-responsive DDS, loaded with the anticancer drug doxorubicin [ 11 ]. The particles were functionalized with transferrin through a pH-sensitive linker as a gatekeeper, controlling the release kinetics and preventing early leakage of the drug [ 11 ]. An interesting breast cancer therapy was published by Mal et al. using doxorubicin as API and mesoporous silica as a carrier [ 65 ]. The amine-functionalized MSNs were PEGylated and then conjugated with folic acid or hyaluronic acid. It was also published that coating the nanoparticles with polydopamine (PDA) and polyethylene glycol (PEG) brings about prolonged doxorubicin release from MSNs [ 77 ]. These conjugates enabled ligand-mediated targeted drug delivery [ 65 ]. Researchers have developed a successful DDS that targets cancer cells, thus staying away from the side effects associated with doxorubicin in conventional cancer therapy. This is important because in vitro cytotoxicity studies have shown that the free drug has higher cytotoxicity than the nanocarriers [ 65 ]. Shahbaz et al. developed a redox-responsive silica nanocarrier loaded with paclitaxel to target breast cancer cells [ 67 ]. The amine-functionalized silica core was coated with disulfide-functionalized non-porous silica shell. Then the core-shell carriers were further coated with polyethylene glycol via disulfide linkages. In vitro drug release assay verified the correlation between the redox potential of the environment and the release kinetics. This is an important finding, as it has been revealed that cancer cells possess a higher redox ability than healthy cells. This provides controlled paclitaxel release for targeted therapy. According to cell uptake and cell viability assays, this DDS is noticeably more effective than free paclitaxel, making this nanocarrier an exciting prospect [ 67 ]. These illustrations highlight the importance of surface functionalization and employing stimuli-responsive gatekeepers to attain productive targeted therapy.

Silica pH Value: Typical pH by Silica Type and Why It Matters

What is silica (SiO₂)?

silica for chromatography

What is the difference between fumed silica and precipitated silica?

silica SDS The immune activation through functional nanocarriers is realized by interactions with innate immune cells such as macrophages, neutrophils, and complement proteins. Immune recognition triggers inflammation, immune responses, or even swift clearance, thus presumably constraining therapeutic effects. Surface properties, such as chemical composition, topography, and charge, may influence the immune cell activation and binding specificity. The possible immune interactions need to be well characterized for the development of stealth and immunocompatible nanoparticles [ 82 ]. Immune-derived side influences, such as cytokine release and complement activation, potentially corrupt the safety and the effectiveness of drug delivery [ 80 ]. Other problems that may affect nanoparticle penetration and the effectiveness of targeting are the heterogeneity of the target tissue and tumor microenvironment. Problems of stability, biodegradation rates, and nanoparticle agglomeration may also affect the effectiveness of action [ 80 ].

What drives silica raw material prices?

silica industry outlook

Cite this article: Silica Raw Materials News. "Silica as a Thixotropic Agent: Mechanism, Dosage and Applications ." Published 2026-11-20 09:06:56. /news/article.html
Disclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.